Wave Life Sciences price target raised to $50 from $47 at Clear Street

8 hours ago 1

TipRanks

Tue, February 3, 2026 astatine 11:30 AM CST 1 min read

Clear Street raised the firm’s terms people connected Wave Life Sciences (WVE) to $50 from $47 and keeps a Buy standing connected the shares aft GSK (GSK) returned the rights to WVE-006 for alpha1-antitrypsin deficiency. The steadfast views the quality arsenic an “overall positive.” The muted banal absorption contiguous is owed to the outsized value of WVE-007 successful Wave Life’s valuation overshadowing its alpha-1 antitrypsin deficiency program, the expert tells investors successful a probe note. Clear Street inactive believes successful the programme contempt GSK’s decision.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected WVE:

Disclaimer & DisclosureReport an Issue

Wave Life Sciences Regains WVE-006 Rights, Plans Accelerated Path
Wave Life Sciences regains afloat rights to WVE-006
3 ‘Strong Buy’ Biotech Stocks to Buy Today, 1/13/2026, According to Top Analysts
Wave Life Sciences sets 2026 strategy, highlights obesity program
Wave Life Sciences highlights priorities for 2026

Read Entire Article